Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 3
1989 4
1990 2
1991 7
1992 1
1993 3
1994 3
1995 2
1996 3
1997 2
1998 2
1999 3
2000 1
2001 3
2002 7
2003 2
2004 4
2005 6
2006 8
2007 6
2008 7
2009 3
2010 9
2011 7
2012 8
2013 8
2014 13
2015 11
2016 17
2017 16
2018 14
2019 18
2020 30
2021 26
2022 27
2023 23
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. Among authors: pontremoli r. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
GLP-1 Receptor Agonists and Kidney Protection.
Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S. Greco EV, et al. Among authors: pontremoli r. Medicina (Kaunas). 2019 May 31;55(6):233. doi: 10.3390/medicina55060233. Medicina (Kaunas). 2019. PMID: 31159279 Free PMC article. Review.
Expanding the therapy options for diabetic kidney disease.
Fioretto P, Pontremoli R. Fioretto P, et al. Among authors: pontremoli r. Nat Rev Nephrol. 2022 Feb;18(2):78-79. doi: 10.1038/s41581-021-00522-3. Nat Rev Nephrol. 2022. PMID: 34862514 No abstract available.
The URRAH study.
Del Pinto R, Viazzi F, Pontremoli R, Ferri C, Carubbi F, Russo E. Del Pinto R, et al. Among authors: pontremoli r. Panminerva Med. 2021 Dec;63(4):416-423. doi: 10.23736/S0031-0808.21.04357-3. Epub 2021 Mar 26. Panminerva Med. 2021. PMID: 33765764
Atherogenic dyslipidemia and diabetic nephropathy.
Russo G, Piscitelli P, Giandalia A, Viazzi F, Pontremoli R, Fioretto P, De Cosmo S. Russo G, et al. Among authors: pontremoli r. J Nephrol. 2020 Oct;33(5):1001-1008. doi: 10.1007/s40620-020-00739-8. Epub 2020 Apr 23. J Nephrol. 2020. PMID: 32328901 Review.
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, Stegbauer J, Judge PK, Preiss D, Emberson J, Trinca D, Dayanandan R, Lee R, Nolan J, Omata A, Green JB, Cherney DZI, Hooi LS, Pontremoli R, Tuttle KR, Lees JS, Mark PB, Davies SJ, Hauske SJ, Steubl D, Brückmann M, Landray MJ, Baigent C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Mayne KJ, et al. Among authors: pontremoli r. J Am Soc Nephrol. 2024 Feb 1;35(2):202-215. doi: 10.1681/ASN.0000000000000271. Epub 2023 Dec 12. J Am Soc Nephrol. 2024. PMID: 38082486 Free PMC article. Clinical Trial.
286 results